

Sun Pharma acquires Pharmeducence

Mumbai, July 16, 2014: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced acquisition of Pharmeducence Inc., by one of its subsidiaries.

Pharmeducence has sterile injectable capacity in the US, supported by strong R&D capabilities.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international specialty pharmaceutical company with over 75% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world. For the year ending March 2014, overall revenues were at US\$2.7 billion, of which US contributed US\$1.6 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Nimish Desai
Tel +91 22 6645 5645, Xtn 5717
Tel Direct +91 22 6645 5717
Mobile +91-98203 30182
E-mail nimish.desai@sunpharma.com

Frederick Castro
Tel +91 22 6645 5645, Xtn 5964
Tel Direct +91 22 6645 5964
Mobile +91 99206 65176
E-mail frederick.castro@sunpharma.com